Through CMap, they aimed to uncover unexplored drug-target connections relevant to NSCLC, which revealed that lymecycline, a semisynthetic derivative of tetracycline, may be useful in overcoming EGFR TKI resistance [43]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.